

Criteria for Poster Abstract Submissions

The purpose of AMDA – The Society for Post-Acute and Long-Term Care Medicine poster session is to bring practical, scientifically sound information of the highest quality to its conference participants so that they can apply new ideas immediately to their practices.

CHARACTER LIMIT: Abstracts are limited to 3,000 characters. Abstract title and author names do *NOT* count toward character limit.

The Annual Conference Program Planning Subcommittee will review poster abstract submissions according to the following guidelines:

- 1. The content of the poster provides an opportunity to share best PALTC practices and outcomes as well as emerging research data with colleagues.
- 2. Pharmaceutical or other medical products discussed in the abstract/poster presentation that are not FDA approved must be accompanied by disclosure. Medications will be referred to only by class and/or generic names.
- 3. Poster submission includes concepts that have immediate practical application.
- 4. Poster submission has relevance to the professional practices of the Society's members and those working in the PALTC setting.
- 5. Poster submissions are entirely non-commercial. Posters may not promote specific medical substances/products.
- 6. Poster presenters of accepted poster abstracts **must be one of the professional authors** (physician, IDT member or healthcare professional-in-training) involved in the research and/or content development and must be present at the onsite presentation times designated for participants to interact with presenters.
- 7. Poster abstracts should not be submitted for previously published work or work that will be printed and disseminated by the time of the Society's Annual Conference.
- 8. Poster abstracts may be submitted for work accepted by a professional journal or other publication but will not be printed or disseminated until after the time of the presentation at the Society's Annual Conference.
- 9. The material presented in the poster must be up-to-date and presented in a balanced and unbiased manner. Comparisons of efficacy, contraindications, modes of administration, etc., between competitive products shall be fully presented. Editorial conclusion should be avoided.
- 10. All poster authors are required to review the Society's Faculty Disclosure Policy. Disclosures for all authors must be included with the poster abstract submission.
- 11. Abstracts with missing documentation will be considered incomplete and will be returned to the submitter.
- 12. The Society conducts a blind review of abstracts, which means author identities and institutions are concealed from the reviewers. The selection process of the review committee is confidential, and its decisions are final. Those who submit poster abstracts agree to accept the decision of the review committee.
- 13. The Subcommittee reserves the right to remove posters displayed at the conference that give the appearance of commercial bias/intent.



Category Criteria

The Annual Conference Program Planning Subcommittee will review poster abstract submissions according to the following guidelines for the specified category:

Case Studies/Reports

- 1. The cases should include a lesson for PALTC providers. Interesting hospital cases may be submitted, but the lesson at the end should be connected to PALTC providers.
- 2. Cases should have been in part at least personally attended to by the Poster Submitter.

Education

1. The abstract should indicate how it is generalizable and to which populations.

Quality Improvement

- 1. All QI Posters should create a <u>SMART aim statement</u> by answering the questions: What are we trying to accomplish? Why do I think this is important? What is the population being targeted? What are the measurable goals?
- 2. All QI Posters should have at least 1 PDSA cycle completed by December 15, 2023.
- 3. All QI posters should have next steps indicated on the submission.

Research

1. The abstract should indicate how it is generalizable and to which populations.